Superworth

IDEAYA Biosciences price to sales ratio IDYA

Market value divided by revenue over the last twelve months, since 2021.

Today, Nov 2, 2026
13.0×
5-year median
22.2×
Against its 5-year history
4th
percentile: 0 is its lowest day, 100 its highest
5-year range
12.5× to 200×
Peer median
2.7×

IDEAYA Biosciences' price to sales ratio is 13.0× as of Nov 2, 2026.

That is below its 5-year median of 22.2×, lower than on 96% of days in the last 5 years.

Over that time it ranged from 12.5× in Sep 2022 to 200× in Jul 2024.

The median for 10 large drugmakers of a similar size is 2.7×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far13.0×13.0×16.5×
2025184×184×184×
2024196×94.1×200×
202397.7×13.0×97.7×
202217.5×12.5×23.0×
202125.6×23.2×29.0×

Against its peers

Companies in Drug Manufacturers - General nearest IDEAYA Biosciences' size, closest first, today.

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on IDEAYA Biosciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.